Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$118.30

-0.99 (-0.83%)

, NBIX

Neurocrine

$90.59

-1.84 (-1.99%)

08:03
03/13/18
03/13
08:03
03/13/18
08:03

AbbVie says Phase 3 ELARIS UF-II study of elagolix met primary endpoint

AbbVie (ABBV) in cooperation with Neurocrine Biosciences (NBIX), announced that the Phase 3 ELARIS UF-II study of elagolix met its primary endpoint. Results from the second of two pivotal Phase 3 studies demonstrated at month six that elagolix, in combination with low-dose hormone therapy, reduced heavy menstrual bleeding with 76.2% of women with uterine fibroids achieving clinical response compared to placebo, as measured by the alkaline hematin method. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50% or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints at month six.

ABBV

AbbVie

$118.30

-0.99 (-0.83%)

NBIX

Neurocrine

$90.59

-1.84 (-1.99%)

  • 13

    Mar

  • 13

    Mar

  • 20

    Mar

ABBV AbbVie
$118.30

-0.99 (-0.83%)

02/21/18
PIPR
02/21/18
NO CHANGE
PIPR
Overweight
Piper says 'hard to quibble with' elagolix efficacy, keeps AbbVie at Overweight
After AbbVie reported that one of its two Phase 3 trials of elagolix in patients with uterine fibroids met its primary efficacy endpoint and all ranked secondary endpoints, Piper Jaffray analyst Christopher Raymond said it was "hard to quibble with the efficacy data." He expects to see 12-month data from both trials later this year or early next, which would set up for a potential uterine fibroids launch in 2020. Raymond, who said he "would not be shocked" if his revenue estimates in this indication prove conservative, keeps an Overweight rating on AbbVie.
02/22/18
NEED
02/22/18
NO CHANGE
Target $110
NEED
Buy
Neurocrine price target raised to $110 from $95 at Needham
Needham analyst Alan Carr raised his price target on Neurocrine (NBIX) to $110 and kept his Buy rating on the stock. Carr cites the positive top-line results from the first of two phase 3 trials of elagolix by Neurocrine's collaborator AbbVie (ABBV) as well as last week's disclosure that the FDA will not require another phase 3 efficacy trial for opicapone. The analyst notes that the added timeline clarity will likely translate into the opicapone NDA submission in the first half of 2019 and a launch in mid-2020.
02/23/18
OPCO
02/23/18
NO CHANGE
Target $110
OPCO
Outperform
Neurocrine 'going for gold,' has 'Midas Touch,' says Oppenheimer
Oppenheimer analyst Jay Olson raised his price target on Neurocrine shares to $110 from $100, citing the positive Phase 3 study results for elagolix in the treatment of uterine fibroids by Neurocrine's collaborator AbbVie (ABBV). Additionally, Olson cited last week's disclosure that the FDA will not require a Phase 3 study in the U.S. for opicapone for the price target increase. Olson told investors in a research note called "Going for Gold -- This Team Has the Midas Touch" that both of these updates are seen as "key de-risking events" and raise the probability of success for both elagolix and opicapone to 90% from 60%. Olson has an Outperform rating on Neurocrine shares.
03/08/18
PIPR
03/08/18
NO CHANGE
Target $138
PIPR
Overweight
AbbVie shares can 'continue to work,' says Piper Jaffray
After hosting a meeting with investors at AbbVie's (ABBV) headquarters this week, Piper Jaffray analyst Christopher Raymond believes the shares can "continue to work." The analyst believes the stock can continue outperforming on "solid" commercial and clinical performance. Management expressed no urgency for a larger commercial or late-stage acquisition, Raymond tells investors in a research note. The analyst says he's glad he never wrote that AbbVie for Biogen (BIIB) research note. He keeps an Overweight rating on AbbVie.
NBIX Neurocrine
$90.59

-1.84 (-1.99%)

02/14/18
OPCO
02/14/18
NO CHANGE
Target $100
OPCO
Outperform
Neurocrine price target raised to $100 from $95 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Neurocrine to $100 from $95 to reflect Q4 financial results, management guidance on expenses and profitability. The analyst reiterates an Outperform rating on the shares.
02/20/18
LEER
02/20/18
NO CHANGE
Target $96
LEER
Outperform
Neurocrine price target raised to $96 from $90 at Leerink
Leerink analyst Paul Matteis raised his price target Neurocrine to $96 from $90 to reflect the company's positive update on opicapone, Q4 results, and bullish commentary from management at his firm recent investor dinner. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

CAG

Conagra Brands

$28.56

-0.46 (-1.59%)

16:32
12/18/18
12/18
16:32
12/18/18
16:32
Hot Stocks
Conagra Brands to divest the Wesson oil brand »

Conagra Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

JBGS

JBG Smith Properties

$36.42

0.05 (0.14%)

16:31
12/18/18
12/18
16:31
12/18/18
16:31
Hot Stocks
JBG Smith Properties declares special cash dividend of 10c per share »

JBG Smith announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$184.11

-4.02 (-2.14%)

16:31
12/18/18
12/18
16:31
12/18/18
16:31
Hot Stocks
L3 Technologies awarded $350M U.S. Air Force contract »

L3 Technologies has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMS

Adamas Pharmaceuticals

$8.11

-0.67 (-7.63%)

16:31
12/18/18
12/18
16:31
12/18/18
16:31
Hot Stocks
Adamas announces issuance of new U.S. patent covering GOCOVRI »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SURF

Surface Oncology

$7.35

-0.44 (-5.65%)

16:30
12/18/18
12/18
16:30
12/18/18
16:30
Hot Stocks
Breaking Hot Stocks news story on Surface Oncology »

Surface Oncology Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
12/18/18
12/18
16:30
12/18/18
16:30
Options
Preliminary option volume of 21.5M today »

Preliminary option volume…

UPS

UPS

$97.25

0.33 (0.34%)

, FDX

FedEx

$185.01

2.81 (1.54%)

16:28
12/18/18
12/18
16:28
12/18/18
16:28
Hot Stocks
FedEx falls after FY19 guidance cut to $15.50-$16.50 from $17.20-$17.80 »

Shares of FedEx (FDX) are…

UPS

UPS

$97.25

0.33 (0.34%)

FDX

FedEx

$185.01

2.81 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

ALKS

Alkermes

$31.83

-1.125 (-3.41%)

16:27
12/18/18
12/18
16:27
12/18/18
16:27
Downgrade
Goldman downgrades Alkermes to Sell ahead of potential schizophrenia launch »

Goldman Sachs analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 31

    Jan

CBS

CBS

$46.21

-0.6 (-1.28%)

, ORCL

Oracle

$45.82

0.1 (0.22%)

16:27
12/18/18
12/18
16:27
12/18/18
16:27
On The Fly
Fly Intel: Wall Street's top stories for Tuesday »

Stocks opened sharply…

CBS

CBS

$46.21

-0.6 (-1.28%)

ORCL

Oracle

$45.82

0.1 (0.22%)

JNJ

Johnson & Johnson

$130.38

1.27 (0.98%)

BA

Boeing

$328.26

11.88 (3.76%)

QCOM

Qualcomm

$57.77

0.78 (1.37%)

AAPL

Apple

$165.81

1.76 (1.07%)

TLRY

Tilray

$76.77

10.88 (16.51%)

NVS

Novartis

$85.40

-0.4 (-0.47%)

NAV

Navistar

$27.59

3.75 (15.73%)

APHA

Aphria

$5.86

0.42 (7.72%)

RCII

Rent-A-Center

$13.02

-1.43 (-9.90%)

LXFR

Luxfer

$18.76

-2.66 (-12.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 18

    Dec

  • 19

    Dec

  • 20

    Dec

  • 20

    Dec

  • 05

    Jan

  • 27

    Jan

LLY

Eli Lilly

$106.56

-1.8 (-1.66%)

, ADRO

Aduro Biotech

$2.49

-0.14 (-5.32%)

16:23
12/18/18
12/18
16:23
12/18/18
16:23
Hot Stocks
Eli Lilly, Aduro announce research collaboration for immunotherapy development »

Eli Lilly (LLY) and Aduro…

LLY

Eli Lilly

$106.56

-1.8 (-1.66%)

ADRO

Aduro Biotech

$2.49

-0.14 (-5.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

MDU

MDU Resources

$24.80

-0.39 (-1.55%)

16:22
12/18/18
12/18
16:22
12/18/18
16:22
Hot Stocks
MDU Resources reports record November backlog of $1.6B »

MDU Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.64

3.33 (2.37%)

, TWTR

Twitter

$33.73

0.31 (0.93%)

16:22
12/18/18
12/18
16:22
12/18/18
16:22
Hot Stocks
Trump claims Facebook, Twitter, Google 'so biased' towards Democrats »

U.S. President Donald…

FB

Facebook

$143.64

3.33 (2.37%)

TWTR

Twitter

$33.73

0.31 (0.93%)

GOOG

Alphabet

$1,028.79

11.19 (1.10%)

GOOGL

Alphabet Class A

$1,043.31

16.77 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

WIN

Windstream

$2.69

0.15 (5.91%)

16:21
12/18/18
12/18
16:21
12/18/18
16:21
Hot Stocks
Windstream sells fiber assets to Arvig in $49.5M cash deal, to sell $11M more »

Windstream announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$6.68

-0.43 (-6.05%)

16:20
12/18/18
12/18
16:20
12/18/18
16:20
Hot Stocks
McDermott signs a lease for new headquarters »

McDermott International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
12/18/18
12/18
16:20
12/18/18
16:20
Options
Closing CBOE SPX and VIX Index summary for December 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIG

Signet Jewelers

$31.23

-0.25 (-0.79%)

16:20
12/18/18
12/18
16:20
12/18/18
16:20
Options
Calls lead puts 10:1 in Signet Jewelers with shares at multi-year lows »

Calls lead puts 10:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$48.42

0.29 (0.60%)

16:19
12/18/18
12/18
16:19
12/18/18
16:19
Hot Stocks
Mercury Systems receives $2.9M follow-on order for SAASM devices »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$106.56

-1.8 (-1.66%)

, ADRO

Aduro Biotech

$2.49

-0.14 (-5.32%)

16:18
12/18/18
12/18
16:18
12/18/18
16:18
Hot Stocks
Eli Lilly, Aduro Biotech announce research collaboration, license agreement »

Eli Lilly and Company…

LLY

Eli Lilly

$106.56

-1.8 (-1.66%)

ADRO

Aduro Biotech

$2.49

-0.14 (-5.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

ADSK

Autodesk

$130.56

3.22 (2.53%)

16:18
12/18/18
12/18
16:18
12/18/18
16:18
Initiation
Autodesk initiated  »

Autodesk initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

PTC

PTC

$83.56

1.23 (1.49%)

16:18
12/18/18
12/18
16:18
12/18/18
16:18
Initiation
PTC initiated  »

PTC initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALKS

Alkermes

$31.83

-1.125 (-3.41%)

16:18
12/18/18
12/18
16:18
12/18/18
16:18
Downgrade
Alkermes rating change  »

Alkermes downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 31

    Jan

LNT

Alliant Energy

$43.91

-0.23 (-0.52%)

16:17
12/18/18
12/18
16:17
12/18/18
16:17
Hot Stocks
Alliant Energy to move its comon stock to Nasdaq »

Alliant Energy will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANSS

Ansys

$150.10

3.71 (2.53%)

16:17
12/18/18
12/18
16:17
12/18/18
16:17
Initiation
Ansys initiated  »

Ansys initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
12/18/18
12/18
16:17
12/18/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$18.87

-0.03 (-0.16%)

16:16
12/18/18
12/18
16:16
12/18/18
16:16
Periodicals
Rice brothers want CEO post at EQT, new board members, WSJ reports »

Toby and Derek Rice, two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.